Literature DB >> 18679628

Oncolytic adenoviruses for cancer gene therapy.

Ta-Chiang Liu1, Stephen H Thorne, David H Kirn.   

Abstract

The use of replication-competent oncolytic viruses has largely advanced cancer gene therapy. Oncolytic virus not only possesses unique mechanisms of action that are distinct from other treatment modalities, its self-perpetuating nature provides an ideal platform for therapeutic transgene insertion. Tumor selectivity can be achieved by deleting viral genes that are critical for growth in normal cells but dispensable in tumor cells, transcriptional control under tumor-specific promoters, fiber modification targeting tumor-specific cellular receptors, or the use of inherent tumor-specific viruses. Transgene products can be amplified along with viral replication, thus maximizing therapeutic effect. Using adenovirus as a template, this chapter describes common assays used for the study of oncolytic viruses, with special emphasis on in vitro and in vivo viral replication determination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18679628     DOI: 10.1007/978-1-59745-237-3_15

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy.

Authors:  Sadia Zafar; Suvi Parviainen; Mikko Siurala; Otto Hemminki; Riikka Havunen; Siri Tähtinen; Simona Bramante; Lotta Vassilev; Hongjie Wang; Andre Lieber; Silvio Hemmi; Tanja de Gruijl; Anna Kanerva; Akseli Hemminki
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

2.  Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer.

Authors:  Alan R Penheiter; Troy R Wegman; Kelly L Classic; David Dingli; Claire E Bender; Stephen J Russell; Stephanie K Carlson
Journal:  AJR Am J Roentgenol       Date:  2010-08       Impact factor: 3.959

3.  Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus.

Authors:  Konstantin Doronin; Elena V Shashkova; Shannon M May; Sean E Hofherr; Michael A Barry
Journal:  Hum Gene Ther       Date:  2009-09       Impact factor: 5.695

Review 4.  State of play and clinical prospects of antibody gene transfer.

Authors:  Kevin Hollevoet; Paul J Declerck
Journal:  J Transl Med       Date:  2017-06-07       Impact factor: 5.531

Review 5.  Oncolytic Virotherapy versus Cancer Stem Cells: A Review of Approaches and Mechanisms.

Authors:  Shyambabu Chaurasiya; Nanhai G Chen; Susanne G Warner
Journal:  Cancers (Basel)       Date:  2018-04-19       Impact factor: 6.639

Review 6.  Methods for improving the immunogenicity and efficacy of cancer vaccines.

Authors:  Lorenzo Pilla; Soldano Ferrone; Cristina Maccalli
Journal:  Expert Opin Biol Ther       Date:  2018-06-17       Impact factor: 4.388

Review 7.  Expression of new antigens on tumor cells by inhibiting nonsense-mediated mRNA decay.

Authors:  Eli Gilboa
Journal:  Immunol Res       Date:  2013-12       Impact factor: 4.505

8.  Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy In Vitro.

Authors:  Rodolfo Garza-Morales; Roxana Gonzalez-Ramos; Akiko Chiba; Roberto Montes de Oca-Luna; Lacey R McNally; Kelly M McMasters; Jorge G Gomez-Gutierrez
Journal:  Cancers (Basel)       Date:  2018-05-17       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.